A research team at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has developed a new ...

The 7 major Chimeric Antigen Receptor (CAR) T-Cell Therapy markets reached a value of US$ 3,979.2 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 12,482.2 Million by 2035, ...

The future of medicine with CRISPR and CAR-T therapy, exploring ethical, societal, and accessibility challenges in healthcare ...

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the ...

Blood cancer patients in Christchurch and Auckland will soon have a chance to join an expanded clinical trial using their own ...

Few advancements in contemporary medicine have sparked as much enthusiasm and potential as CAR T-cell therapy.

A research team at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has developed a new protein capable of improving ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...